SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (68)6/11/1997 1:34:00 AM
From: Mike Winn   of 399
 
How do you compare the royalty received by ARQL to the one received by let say,
Incyte (INCY)? Does ARQL have a molecule database like INCY? We can
may be predict the future valuation of ARQL based on INCY and the
number of contracts that have been signed. I am not very proficient in
the biotech field so does anyone know if INCY has any contract that results
into real product?

IMHO, the contract with Mosanto is the most promising one for ARQL since
it does not involve drug and can more likely result into real product.

Mike.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News